Identifying Gaps in Rabies Post-Exposure Prophylaxis in Hunan Province, China

Marie Keith MPH Candidate Kansas State University April 18, 2018

The Global Burden of Canine Rabies

Hamspon et al. 2015

Est. 59,000 deaths annually *Under-reporting*

> 3.7 million DALYs/ year

8.6 Billion USD/ year PEP costs: 20% Income lost while seeking PEP: 15%



Global Epidemiology

Presence of dog-transmitted human rabies based on most recent data points from different sources, 2010-2014





Rabies in China

- 2nd highest burden globally
 - 1950 2010: avg 2,037 cases/year
 - 2007: 3,300 cases
- Risk Factors
 - Male
 - Rural
 - Farmer
 - < 15 or > 50
 - Dog bite
 - Southern provinces
- 12 15 million doses PEP/year



Rabies Prevention & Biologics

#1: Eradicate canine rabies

#2: Appropriate risk-based PrEP and PEP

Anti-Rabies Vaccines (ARVs)

Nerve Tissue Vaccines: available since 1885
Cell Culture Vaccines: available since 1970s

Rabies Immunoglobulin (RIG)

- Human RIG
- Equine RIG misconceptions about safety

> 29 million peoplereceive PEP annually inrabies endemic regions

When used appropriately, rabies PEP is extremely safe & effective

WHO Exposure Categories and Treatments

Categories of contact with suspect	Activity/Wound Description	Post-exposure prophylaxis measures		
rabid animal	Activity/ wound Description			
Category I	Touching or feeding animals, licks on intact skin	None		
Category II	Nibbling of uncovered skin, minor scratches or	Immediate vaccination and local treatment of the		
	abrasions without bleeding	wound (ARVs)		
		Immunocompromised persons [§] with a Category II		
		exposure should also receive rabies		
		immunoglobulin. (ARVs + RIG)		
Category III	Single or multiple transdermal bites or scratches,	Immediate vaccination and administration of		
	licks on broken skin; contamination of mucous	rabies immunoglobulin; local treatment of the		
	membranes with saliva from licks, contact with	wound (ARVs + RIG)		
	bats.			

[§]Immunocompromised persons include any patient with an illness such as HIV, TB or cancer or other illnesses known to suppress the immune system. Also included are patients that have been on an immunosuppressive medication for any reason prior to a rabies exposure.

Source Data: http://www.who.int/mediacentre/factsheets/fs099/en/; http://www.who.int/rabies/PEP_prophylaxis_guidelines_June10.pdf

WHO-Approved PEP Vaccine Regimens

Intramuscular Route (0.5 – 1.0 ml at each site, depending on vaccine)					
5-dose ("Essen") Regimen	1 dose each on days:				
	0, 3, 7, 14, 28				
4-dose ("Zagreb") Regimen	1 dose at each of 2 sites on day 0;				
(also referred to as "2-1-1")	1 dose each on days: 7, 21				
Modified 4-dose Regimen [‡] + RIG*	1 dose each on days: 0, 3, 7, 14				
	*RIG <u>must</u> also be administered				
	[‡] May not be used on sick or immunocompromised persons [§]				
Intradermal Route (0.1 ml at each of 2 sites)					
Updated Thai Red Cross Regimen	1 dose at each of 2 sites on days:				
	0, 3, 7, 28				
PEP for patients who have already received Pre-Exposure Prophylaxis (PrEP)					
Intramuscular	1 dose each on days:				
	0, 3				
Intradermal	1 dose at each of 4 sites on day 0				

Minimum 3 visits to PEP clinic

Significant volume reduction with ID compared to IM

China Centers for Disease Control & Prevention

- Formed in 2002 (SARS)
- Goals:
 - (1) disease prevention and control
 - (2) scientific research
 - (3) workforce development
- ~ 2,100 staff



China CDC & Rabies: 0 by 2025



PEP Failures in China

- 12 15% rabies cases did visit a PEP clinic
- What went wrong?
 - Compliance?
 - Inappropriate delivery of PEP?



Assess this via a Pilot Study

Image Source: http://www.who.int/neglected_diseases/news/Rabies_WHO_has_published_new_recommendations_for_immunization/en/

Study Goals & Questions:

Develop tools to assess preparedness of rabies PEP clinics, staff training, PEP delivery

- Resources at rabies PEP clinics?
- Demographics of persons seeking PEP?
- Are exposures accurately classified by healthcare workers?
- Is the appropriate treatment protocol selected?

Identify Gaps in PEP knowledge and practices

Pilot Study: Shuangfeng County, Hunan Province (May – August, 2016)

- High incidence of rabies
- Pop. 850,000
- 5,000 courses of PEP (588/100,000 persons) annually



Pilot Design: Two Survey Assessment



May - June:

Personnel, Facilities and Hours, Biologics, Equipment, Information Management

16 clinic sites66 healthcare workers

Survey 2: PEP Delivery

July 20 – August 4:

Patients presenting for bite/scratch wounds followed from admission to discharge by 3rd party CDC staff members

> 7 clinics 196 Patients

I arrived at China CDC to start my Field Experience **Analysis** August 2016 – April 2018

Qualitative and Descriptive approach

Survey 1: Clinic Capabilities Rabies Biologics and Adverse Event Preparedness

Rabies Biologics	Equipment & Emergency Preparedness
 Regimen: Essen (5-dose IM) 	 Refrigerators: 16/16

- ARVs Cost: 290 375 RMB (\$46 \$59) per person
- RIG Supply: Only 1/16 clinics had RIG in stock (HRIG)
- RIG cost: 250 RMB/vial (\$40)

- Epinephrine: 15/16
- Dexamethasone: 13/16





Patients Presenting for Bite/Scratch Wounds July 20 and August 4, 2016



Survey 2: PEP Delivery Demographics of Patients Presenting for Bite/Scratch Wounds



Males Females

Wound Source: Species, Ownership, Animal's Vaccination Status

	Number	% of Total	% of Domestic animals
Dogs	140	71.4	
Owned by patient's family	67	34.2	
Owned by someone else	27	13.8	
Unknown	15	7.7	
Not inquired	31	15.8	
Cats	38	19.4	
Owned by patient's family	26	13.3	
Owned by someone else	2	1.0	
Unknown	2	1.0	
Not inquired	8	4.1	
Domestic animals (owned dogs and cats)	122	62.2	
Vaccinated	1		0.8
Unvaccinated	2		1.6
Not inquired	119		97.5
Rats	16	8.2	
Human	1	0.5	
Unknown	1	0.5	

Does it matter if the animal is vaccinated?

Exposure Method and WHO Categorization

WHO Exposure Category	Exposure Method	Number of Patients	%	Number of Patients	%
	Touching/feeding animals	0	0		
I	Lick on intact skin	4	2	5	2.5
	"Other"	1	0.5		
	Nibbling at exposed skin 35 17.9				
II	Minor scratch or abrasion without bleeding	68	34.7	103	52.6
III	Penetrating skin bite(s) or scratch(es)	87	44.4		
	Lick on area of broken skin 1 0.5		0.5	88	44.9
	Open wound or mucous membrane contamination	0	0		

Exposure Categorization: WHO compared to HCW

WHO Category	# Patients	Exposure Category applied by HCW	# Patients	% of Category	% of Total
		I	2	40	1
I	5	II	3	60	1.5
		III	0	0	0
II 103		l	9	8.7	5
	103	II	94	91.3	48
		III	0	0	0
		I	3	3.4	1.5
III	88	II	34	38.6	17
		III	51	58	26

25% of Patients mis-categorized

23.5% of Patients under-categorized

Survey 2: PEP Delivery Relevant Medical History-Taking

HCW asked about:				
58%	patient's rabies vaccination status			
9.2%	possible immunocompromised status due to disease (HIV, TB, cancer)			
0%	use of immunosuppressive drugs			
13%	history of drug/vaccine allergies			

Wound Care Summary

	# of patients whose wound (%)	was washed	Appropriately washed (%)
WHO Category II and III	by HCW:	1 (0.5)	0 (0)
(191 patients)	by patient/accompanying person:	151 (79)	95 (49.7)
	at another facility:	4 (2)	?
	at home:	26 (13.5)	4 (2.1)
	Not washed:	9 (5)	N/A
			Total: 99/191 = 51.8%
HCW Category II and III (182 patients)	by HCW:	1 (0.5)	0 (0)
	by patient/accompanying person:	140 (77)	85 (47)
	at another facility:	4 (2)	?
	at home:	27 (15)	6 (3)
	Not washed:	10 (5.5)	N/A
			Total: 91/182 = 50%

ARVs Initiated: Improper Patient Selection

Exposure Type	# Total Patients	# Patients receiving ARV (%)	
WHO Category I	5	5 (100)	2.5% of Patients incorrectly received ARVs
WHO Category II	103	103 (100)	
WHO Category III	88	87 (99)	
HCW Category I	14	14 (100)	HCWs incorrectly
HCW Category II	131	131 (100)	selected 7% of patients to receive ARVs based on
HCW Category III	51	50 (98)	their own evaluation of the exposure
Total Patients	196	195 (99)	

2/195 (1%) vaccines administered were past the expiration date.

Survey 2: PEP Delivery Patients Receiving RIG by Exposure Category (WHO and HCW)



*1 of these patients had previously been vaccinated for rabies and did not require RIG.

Why was RIG not administered?

	Proportion of Patients who did Not Receive RIG (%)	HCW did not recommend RIG (%)	Patient did not consider RIG to be necessary (%)	RIG not available at the clinic (%)	RIG was cost prohibitive (%)	Patient was referred elsewhere (%)
Category I (HCW)	14/14 (100)	2 (14.3)	10 (71.4)	2 (14.3)	-	-
Category II Immunocompetent (HCW)	126/126 (100)	104 (81)	10 (8)	11 (8)	1 (1)	-
Category II Immunocompromised (HCW)	5/5 (100)	2 (40)	-	2 (40)	1 (20)	-
Category III (HCW)	13/51 (25)	7 (54)*	5 (38)	-	-	1 (8)

*1 was previously vaccinated

30% of cases in which RIG was not administered, a non-valid reason was cited by the HCW



HCWs do not understand the rationale behind RIG administration

Patients Receiving Adequate HRIG Dose

- HRIG: Body Weight-dependent dose (20 IU/kg)
- 63%: Body weight of patient measured (24/38)
 - **54%:** Correct volume administered according to weight (13/24)
 - 46%: Patient under-dosed in cases where body weight was measured (11/24)

14.6% of patients who should have received RIG according to WHO guidelines received a sufficient dose of RIG.

Project Limitations

- Observational Study \rightarrow systematic bias
 - Study site selection
 - Information bias: selective recall of patients
 - Selection bias: patients had to voluntarily agree to be followed
 - Quality of observer information
- Pilot Study
- Sample size
- Impacts of flooding on PEP-seeking behaviors?
- Length

Gaps Identified

Clinic equipment and preparedness

Recognizing exposure levels

Taking Relevant Medical History

Selecting risk-based treatment plans

Administering PEP treatments

Communicating risks to patients

Rabies Control: The Bigger Picture



Acknowledgments

- Dr. George Gao and Dr. Li Yu, China CDC
- Dr. Sally Davis, Dr. Natalia Cernicchiaro and Dr. MM Chengappa, MPH Committee
- Dr. Shi, US-China Center for Animal Health
- KSU CVM International Programs Office
- KSU Master of Public Health Program



Partial Reference List

- WHO | Epidemiology and Burden of Disease <u>http://www.who.int/rabies/epidemiology/en/</u>. Accessed 3/21/2018, 2018.
- CDC | Rabies Prevention <u>https://www.cdc.gov/rabies/prevention/index.html</u>. Accessed 3/21/2018, 2018.
- Hampson K, Coudeville L, Lembo T, et al. Estimating the global burden of endemic canine rabies. *PLoS Negl Trop Dis*. 2015;9(4):e0003709. doi: 10.1371/journal.pntd.0003709 [doi].
- Singh R, Singh KP, Cherian S, et al. Rabies epidemiology, pathogenesis, public health concerns and advances in diagnosis and control: A comprehensive review. *Vet Q*. 2017; 37(1):212-251. doi: 10.1080/01652176.2017.1343516 [doi].
- Dietzschold B, Li J, Faber M, Schnell M. Concepts in the pathogenesis of rabies. Future virology. 2008; 3(5):481-490. doi:10.2217/17460794.3.5.481.
- Song M, Tang Q, Rayner S, et al. Human rabies surveillance and control in china, 2005-2012. BMC Infect Dis. 2014; 14:212-2334-14-212. doi: 10.1186/1471-2334-14-212 [doi].
- Zhang J, Jin Z, Sun GQ, Zhou T, Ruan S. Analysis of rabies in china: Transmission dynamics and control. PLoS One. 2011; 6(7):e20891. doi: 10.1371/journal.pone.0020891 [doi].
- Ren J, Gong Z, Chen E, et al. Human rabies in Zhejiang province, china. Int J Infect Dis. 2015; 38:77-82. doi: 10.1016/j.ijid.2015.07.013 [doi].
- Qi L, Su K, Shen T et al. Epidemiological characteristics and post-exposure prophylaxis of human rabies in Chongqing, China, 2007-2016. BMC Infectious Diseases. 2018; 18(6): 10.1186/s12879-017-2830-x [doi].
- Zhou H, Vong S, Liu K et al. Human Rabies in China, 1960-2014: A Descriptive Epidemiological Study. PLoS Negl Trop Dis. 2016; 10(8): e0004874.doi:10.1371/journal.pntd.0004874 [doi].
- Yin W, Dong J, Tu C, et al. Challenges and needs for China to eliminate rabies. Infectious Diseases of Poverty. 2013; 2:23. doi:10.1186/2049-9957-2-23.
- Mindekem R, Lechenne MS, Naissengar KS et al. Cost description and comparative cost efficiency of post-exposure prophylaxis and canine mass vaccination against rabies in N'Djamena, Chad. *Front. Vet. Sci.* 2017; 4(38): doi.10.3389fvets.2018.00038. [doi].
- Lavan RP, King AIM, Sutton DJ, Tunceli K. Rationale and support for a One Health program for canine vaccination as the most cost-effective means of controlling zoonotic rabies in endemic settings. *Vaccine*. 2017; 35: 1668-1674.
- Si H, Guo ZM, Hao YT et al. Rabies trend in China (1990 2007) and post-exposure prophylaxis in Guangdong province. *BMC Infectious Diseases*. 2008; 8(113): 10.1186/1471-2234-8-113. [doi].
- Chinese Center for Disease Control and Prevention http://www.chinacdc.cn/en/aboutus/orc/. Accessed 3/21/2018, 2018. WHO | rabies http://www.chinacdc.cn/en/aboutus/orc/. Accessed 3/21/2018, 2018. WHO | rabies http://www.chinacdc.cn/en/aboutus/orc/. Accessed 3/21/2018, 2018. WHO | rabies http://www.who.int/mediacentre/factsheets/fs099/en/. Accessed 3/21/2018, 2018.
- Zhou H, Li Y, Chen RF, et al. Technical guideline for human rabies prevention and control (2016). Chinese Center for Disease Control. Zhonghua Liu Xing Bing Xue Za Zhi. 2016; 37(2): 139-63. Doi: 10.3760/cma.j.issn.0254-6450.2016.02.001.
- Kularatne SAM, Ralapanawa DMPUK, Weerakoon K, Bokalamulla UK, Abagaspitiya N. Pattern of animal bites and post-exposure prophylaxis in rabies: A five year study in a tertiary care unit in Sri Lanka. *BMC Infectious Diseases*. 2016; 16:62. DOI 10.1186/s12879-016-1394-5.
- Poorolajal J, Babaee I, Yoosefi R, Farnoosh F. Animal bite and deficiencies in rabies post-exposure prophylaxis in Tehran, Iran. Arch Iran Med. 2015; 18(12):822-826. doi: 0151812/AIM.006 [doi].
- Tricou V, Bouscaillou J, Kamba Mebourou E, Koyanongo FD, Nakoune E, Kazanji M. Surveillance of canine rabies in the Central African Republic: Impact on human health and molecular epidemiology. *PLoS Negl Trop Dis.* 2016; 10(2):e0004433. doi: 10.1371/journal.pntd.0004433 [doi].
- Bariya BR, Patel SV, Shringarpure KS. Comparison of Compliance of Animal Bite Patients to Two Different Routes of Post-Exposure Prophylaxis against Rabies. *Healthline Journal*. 2015; 1:30-35.







Thank You!











